A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 in Male and Female Participants Aged 18 to 64 with Classic DM1
Latest Information Update: 05 Mar 2025
At a glance
- Drugs ARTHEx 01 (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; First in man
- Acronyms ArthemiR
- Sponsors ARTHEx Biotech
Most Recent Events
- 28 Feb 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.
- 28 Feb 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2026.
- 04 Jun 2024 Status changed from not yet recruiting to recruiting.